All In Biotech

Drug Trial Radar · NCT07748208

A Study Evaluating the Safety of Inavolisib and Fulvestrant With or Without Palbociclib in Participants With Advanced Breast Cancer (ABC) and Type 2 Diabetes

A Phase II Prospective, Open-Label Safety Study of Inavolisib and Fulvestrant With or Without Palbociclib in Participants With PIK3CA-Mutated Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer and Type 2 Diabetes

Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

40

Planned (sponsor's estimate)

Start

Nov 30, 2026

Primary completion

Jun 15, 2029

Study completion Sep 30, 2029

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Aug 5, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the safety of inavolisib in combination with fulvestrant, with or without palbociclib, in participants with PIK3CA-mutated, HR+, HER2-negative ABC and type 2 diabetes.

Conditions

  • Breast Cancer
  • Diabetes Type II

Interventions

  • InavolisibDrug

    Participants will receive oral inavolisib on Days 2-28 of each 28-day cycle.

  • FulvestrantDrug

    Participants will receive intramuscular (IM) fulvestrant on Days 1 and 15 of Cycle 1, and then on Day 1 of each subsequent 28-day cycle.

  • PalbociclibDrug

    Some participants will receive oral palbociclib on Days 1-21 of each 28-day cycle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Grade 4 Hyperglycemia Adverse Events (AEs) After Cycle 1Time frame: Up to approximately 21 months
  2. Percentage of Participants Hospitalized for Hyperglycemia or its Complications After Cycle 1Time frame: Up to approximately 21 months
  3. Percentage of Participants with AEs After Cycle 1Time frame: Up to approximately 21 months

Locations

13 sites in 2 countries. Site status is shown where the registry gives one.

  • Community Cancer Institute (CCI)

    Clovis, California · Recruiting

  • The Lundquist Institute for BioMedical Innovation at Harbor-UCLA Medical Cente

    Torrance, California · Recruiting

  • MedStar Washington Hosp Center

    Washington D.C., District of Columbia · Recruiting

  • Grady Memorial Hospital

    Atlanta, Georgia · Recruiting

  • Emory University Hospital Midtown

    Atlanta, Georgia · Recruiting

  • Emory University Hospital

    Atlanta, Georgia · Recruiting

  • Nebraska Cancer Specialists St Francis - Grand Island

    Grand Island, Nebraska · Recruiting

  • Nebraska Cancer Specialists

    Omaha, Nebraska · Recruiting

  • NYU Langone Hospital Long Island Clinical Research

    Mineola, New York · Recruiting

  • NYU Langone?s Perlmutter Cancer Center - 160 E 34th St

    New York, New York · Recruiting

  • West Cancer Center & Research Institute

    Germantown, Tennessee · Recruiting

  • West Virginia University

    Morgantown, West Virginia · Recruiting

  • Pan American Center for Oncology Trials, LLC

    Dorado, Puerto Rico · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.